Pascal Neuville is the founder of Domain Therapeutics. Domain Therapeutics has raised $53M in total funding. Latest round: Series A.
Pascal Neuville is the CEO of Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology. The French-Canadian company secured a $42 million Series A financing round in May 2022 to accelerate the clinical development of its immuno-oncology programs. Previously, Domain Therapeutics raised €6 million in debt financing in January 2020 and €3.5 million from an existing shareholder in 2019.
Full founder directory · Investor directory · Company funding database · Fundraising library